Cat. No. 3242
Chemical Name: 1,4-Dihydro-4-[3-[[[[3-[4-(3-methox
Biological ActivityPotent, competitive neuropeptide (NPY) Y1 antagonist (Ki = 3.3 nM, IC50 = 5.9 nM) that displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over σ1, α1, Y2, Y4 and Y5 receptors respectively. Reduces food intake and body weight via central Y1 inhibition and is brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Antal-Zimanyi et al (2008) Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y1 receptor antagonist Eur.J.Pharmacol. 590 224. PMID: 18573246.
Poindexter et al (2004) Dihydropyridine neuropeptide Y Y1 receptor antagonists 2: bioisosteric urea replacements Bioorg.Med.Chem. 12 507. PMID: 14723969.
Poindexter et al (2002) Dihydropyridine neuropeptide Y Y1 receptor antagonists. Bioorg.Med.Chem.Letts. 12 379.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BMS 193885 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BMS 193885, supplier, Potent, competitive, NPY, Y1, antagonists, Peptide, Receptors, Neuropeptide, Y, BMS193885, neuropeptides, Tocris Bioscience, NPY Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
March 18 - 22, 2017
Little Rock, ARK, USA